目的：特应性皮炎（atopic dermatitis,AD）是一种常见的慢性瘙痒性和炎症性皮肤病。其中大部分病情轻至中度，主要治疗方法为局部外用药物。克立硼罗软膏是一种磷酸二酯酶 4（phosphodiesterase 4(PDE4)）抑制剂，于 2020 年在我国获批用于轻中度特应性皮炎的局部外用治疗，临床疗效好，安全性高，不良反应少，患者可耐受。本文通过查阅相关国内外文献，对克立硼罗治疗 AD 的最新研究进展作一综述。
关键词 / Keywords
关键词：特应性皮炎；治疗；PDE4 抑制剂；克立硼罗
参考文献 / References（引用的文献）：本文研究的参考依据
引证文献 / Cited by（被引用的文献）：引用本文作为参考依据的文献
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
[1]Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109-1122. doi: 10.1016/S0140-6736(15)00149-X. Epub 2015 Sep 13. PMID: 26377142. [2]Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol 2018;120:34-41. [3]Pfizer Inc.; U.S. FDA Approves Supplemental New Drug Application sNDA for Expanded Indication of EUCRISA® Crisaborole Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis[J]. Medical Letter on the CDC & FDA,2020. [4]Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, Jones-Iatauro S, Sexton H, Martin S, Dee J, Mak Y, Meewan M, Rock F, Akama T, Jarnagin K. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes. J Pharmacol Exp Ther. 2016 Sep;358(3):413-22. doi: 10.1124/jpet.116.232819. Epub 2016 Jun 27. PMID: 27353073. [5]Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. J Drugs Dermatol. 2016 Apr;15(4):390-6. PMID: 27050693. [6]Magano Javier. Application of transition metal catalysis to a borylation step for the synthesis of crisaborole[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY,2018,256. [7]Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, Ports WC, Purohit V, Takiya L, Werth JL, Zang C, Vlahos B; CARE 1 Investigators. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). Am J Clin Dermatol. 2020 Apr;21(2):275-284. doi: 10.1007/s40257-020-00510-6. PMID: 32212104; PMCID: PMC7125059. [8]Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, Ports WC, Purohit V, Takiya L, Werth JL, Zang C, Vlahos B; CARE 1 Investigators. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). Am J Clin Dermatol. 2020 Apr;21(2):275-284. doi: 10.1007/s40257-020-00510-6. PMID: 32212104; PMCID: PMC7125059. [9]林杨杨,廉佳,宫泽琨,卞亚伟,刘欣欣,毕田田,王莹,冯小燕,李钦峰.克立硼罗软膏治疗儿童轻中度特应性皮炎 65 例疗效观察[J].中国实用儿科杂志,2021,36(09):693-696.DOI:10.19538/j.ek2021090 6012. [10]沈祺彦,朱越,何子莹,杨圣菊.序贯外用地奈德乳膏与克立硼罗软膏治疗轻中度特应性皮炎的疗效和安全性[J].中国临床医学,2023,30(01):111-115. [11]Martín-Santiago A, Puig S, Arumi D, Rebollo Laserna FJ. Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. Curr Ther Res Clin Exp. 2022 Jun 23;96:100679. doi: 10.1016/j.curtheres.2022.100679. PMID: 35846836; PMCID: PMC9278032. [12]Thom H, Cheng V, Keeney E, Neary MP, Eccleston A, Zang C, Cappelleri JC, Cha A, Thyssen JP. Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis. Dermatol Ther (Heidelb). 2022 Jan;12(1):185-194. doi: 10.1007/s13555-021-00646-1. Epub 2021 Dec 8. PMID: 34877623; PMCID: PMC8776944. [13]Zhao S, Hwang A, Miller C, Lio P. Safety of topical medications in the management of pediatric atopic dermatitis: an updated systematic review. Br J Clin Pharmacol. 2023 Apr 19. doi: 10.1111/bcp.15751. Epub ahead of print. PMID: 37075252. [14]Weil C, Adiri R, Chodick G, Gersten M, Cohen Barak E. Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel. Clin Cosmet Investig Dermatol. 2022 Jun 30;15:1205-1211. doi: 10.2147/CCID.S359625. PMID: 35795722; PMCID: PMC9252191. [15]Li L. Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia. Rev Assoc Med Bras (1992). 2023 Feb 17;69(1):97-100. doi: 10.1590/1806-9282.20220801. PMID: 36820717; PMCID: PMC9937623. [16]Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole. J Dermatolog Treat. 2019 Mar;30(2):156-157. doi: 10.1080/09546634.2018.1480747. Epub 2018 Jun 8. PMID: 29812961. 作者简介： 通信作者：王生（1978-）男，河北唐山人，主任医师，研究方向：银屑病及皮肤外科学 第一作者：郭佳敏（1998-）女，四川眉山人，在读硕士，研究方向：皮肤病与性病学
